Akorn, Inc. And GeneraMedix Sign Commercial Manufacturing Supply Agreement
Arthur S. Przybyl, President and Chief Executive Officer of Akorn stated, "We are excited to enter into this strategic product supply partnership with GeneraMedix. This partnership will allow us to expand our existing market share and increase our contract sales revenues. We believe that GeneraMedix and their executive management team have the experience and infrastructure to successfully market these generic products to the hospital and specialty pharmaceutical markets. We look forward to a long-standing and successful relationship with GeneraMedix."
Ronald F. Quadrel, President and Chief Executive Officer of GeneraMedix stated, "We are very pleased to enter into this strategic relationship with Akorn as we continue to build our injectable product portfolio. The addition of these products reinforces our long term commitment to provide a broad range of generic injectable products to hospitals, surgery centers and clinics."
About Akorn, Inc.
Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com.
About GeneraMedix, Inc.
GeneraMedix, Inc. is a pharmaceutical company offering high quality injectable generic products to the hospital and specialty markets. In addition to its products already marketed, GeneraMedix has a significant number of injectable products under development, as well as a number of products currently under FDA review. Headquartered in Liberty Corner, New Jersey, the company was founded in July of 2004. Additional information is available at the company's website at www.generamedix.com.
Materials in this press release may contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.
Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual results may vary materially, and there are not guarantees about the performance of our stock.
Any forward-looking statements represent our expectations or forecasts only as of the date they were made and should not be relied upon as representing our expectations or forecasts as of any subsequent date. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, even if our expectations or forecasts change. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Such factors include, but are not limited to, risks and uncertainties relating to the resolution of the FDA compliance issues at our Decatur, Illinois manufacturing facility. Other factors besides those listed there could also adversely affect our results.
Contact: Akorn, Inc. Arthur S. Przybyl, 847-279-6100 or GeneraMedix, Inc. Ronald F. Quadrel, 908-504-1301
Source: Akorn, Inc.